Suven Life Sciences Ltd (Suven) announces today that the grant of one (1) product patent from Australia (2014404001), one (1) product patent from Eurasia (029365) and one (1) product patent from Europe (3099675) corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034.
The granted claims of the patents include the class of selective 5-HT4 compound and is being developed as therapeutic agents for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Narcolepsy, Parkinson and Schizophrenia respectively.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally" says Venkat Jasti, CEO of Suven.
Shares of SUVEN LIFE SCIENCES LTD. was last trading in BSE at Rs.184.45 as compared to the previous close of Rs. 189.85. The total number of shares traded during the day was 46319 in over 542 trades.
The stock hit an intraday high of Rs. 191.7 and intraday low of 183. The net turnover during the day was Rs. 8661191.